Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the favorit study

Clinical Transplantation

Volumn 26, Issue 4, 2012, Pages

  Carpenter, Myra A ^a   Weir, Matthew R ^b   Adey, Deborah B ^c   House, Andrew A ^d   Bostom, Andrew G ^e   Kusek, John W ^f  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e RHODE ISLAND HOSPITAL   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cardiovascular disease; Cardiovascular risk factors; Kidney transplantation; Medical management; Medications

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG USE; EVIDENCE BASED PRACTICE; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DISEASE MANAGEMENT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; HYPERTENSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 84864956194     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01676.x     Document Type: Article

References (34)

1. Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol 2000: 20: 176.
2. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000: 11: 1735.
3. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006: 82: 603.
4. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003: 108: 2154.
5. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004: 4: 1662.
6. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007: 18: 2644.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004: 351: 1296.
8. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003: 75: 1291.
9. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010: 375: 073.
10. Weiner DE, Carpenter MA, Levey AS et al. Baseline kidney function and risk of CVD and all cause mortality in stable kidney transplant recipients. Joint Conference - Nutrition, Physical Activity and Metabolism and Cardiovascular Disease Epidemiology and Prevention. Atlanta, GA; 2011.
11. Pilmore HL, Skeans MA, Snyder JJ, Israni AK, Kasiske BL. Cardiovascular disease medications after renal transplantation: results from the patient outcomes in renal transplantation study. Transplantation 2011: 91: 542.
12. Bostom AG, Carpenter MA, Hunsicker L et al. Baseline characteristics of participants in the folic acid for vascular outcome reduction in transplantation (FAVORIT) trial. Am J Kidney Dis 2009: 53: 121.
13. Bostom AG, Carpenter MA, Kusek JW et al. Rationale and design of the folic acid for vascular outcome reduction in transplantation (FAVORIT) trial. Am Heart J 2006: 152: 448.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.
15. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004: 43: S1.
16. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009: 150: 604.
17. 2. Am J Kidney Dis 2010: 56: 486.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002: 39: S1.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972: 18: 499.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001: 285: 2486.
21. Eknoyan G, Levin A, Levin N. K/DOQ1 clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003: 41: S6.
22. Lemahieu WPD, Hermann M, Asberg A et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005: 5: 2236.
23. Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007: 99: 47C.
24. Cowan BR, Young AA, Anderson C et al. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination with ramipril global endpoint trial [ONTARGET]). Am J Cardiol 2009: 104: 1484.
25. Konstam MA, Neaton JD, Dickstein K et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009: 374: 1840.
26. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997: 349: 747.
27. Haller H, Ito S, Izzo JL et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011: 364: 907.
28. Tobe SW, Clase CM, Gao P et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND Studies. Circulation 2011: 123: 1098.
29. Gossmann J, Thürmann P, Bachmann T et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996: 50: 973.
30. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999: 341: 1725.
31. Gowdak LHW, de Paula FJ, César LAM et al. Screening for significant coronary artery disease in high-risk renal transplant candidates. Coron Artery Dis 2007: 18: 553.
32. Sung RS, Althoen M, Howell TA, Ojo AO, Merion RM. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation 2001: 71: 1752.
33. Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000: 72: 324.
34. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001: 60: 1106.